急性髓性白血病治疗方法和结果的差异
Ann-Kathrin Eisfeld1,2,3
1The Ohio State University Comprehensive Cancer Center.
Current opinion in hematology
|December 7, 2023
概括
在急性髓性白血病 (AML) 中,黑人患者的生存差异仍然存在. 诸如社会贫困,试验准入,种族主义和遗传差异等因素导致结果较差,需要紧急干预.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 健康差距 研究 研究 研究 研究
背景情况:
- 黑人和非西班牙裔白人的急性髓性白血病 (AML) 患者之间存在持续的生存差异.
- 已经确定了多种促成因素,往往对患者的治疗结果产生相加的不良影响.
研究的目的:
- 审查和总结急性髓性白血病 (AML) 生存差异的各种贡献者.
- 专注于非裔美国人 (黑人) 患者,考虑自我报告的种族和祖先.
- 要突出影响AML患者生存的因素的相互联系.
主要方法:
- 文献审查侧重于社会剥夺,临床试验招生,生物银行,结构性种族主义和遗传特征.
- 对检查急性髓性白血病 (AML) 存活结果的研究分析.
- 考虑自我报告的种族和遗传祖先.
主要成果:
- 社会贫困,临床试验入学率有限,结构性种族主义显著影响AML生存结果.
- 新兴数据揭示了遗传特征的祖先相关差异,包括AML驱动突变,影响预后.
- 这些因素共同导致不良结果,并强调了AML存活差异的复杂性.
结论:
- 解决AML的生存差异需要针对社会经济地位和试验准入等可修改因素的干预措施.
- 了解与遗传祖先相关的生物差异对于提高预后准确性和治疗策略至关重要.
- 考虑社会,环境和生物因素的综合方法对于减少AML存活差距至关重要.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.4K
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
3.2K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Bone Marrow Sampling and Transplants
333
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
333
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
Comparing the Survival Analysis of Two or More Groups
197
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
197
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
